Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories
BioBlast®
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Litigation
Patents
PipCast®
PTE
Webinars
  • Our Awards
  • Our Capabilities
  • Our People
    • Naomi Pearce
    • Katrina Crooks
    • Jacinta Flattery O’Brien PhD
    • Grant Shoebridge PhD
    • Kate Legge
    • Lesley White
    • Alex May
    • Belinda Hartmann PhD
    • Adele Chadwick
    • Christopher Coates
    • Emily Bristow
    • Brittany Deleon
    • Bronwen Duke
    • Erni Othman
    • Amber Cross
  • Blog
  • BioBlast®
  • E-Books
    • Australia’s Rocket Patent Register: From Application to Patent in a Few Months
    • Entering National Phase in Australia
    • Exclusive Licences
    • Patent linkage in Australia and New Zealand
    • Patent Litigation in Australia
    • Pharmaceutical Patent Term Extensions (PTE) in Australia
    • The 2-Minute Guide to Australian Patent Oppositions
    • The one-minute guide to life sciences patent eligibility in the US, Europe and Australia
    • Australian Patent Cases Review 2021
    • Patent Re-Examination in Australia
  • Webinars
  • Diversity
  • Careers
  • Contact Us

Home / News / BioBlast®

EU’s CHMP recommends the approval of AVT02 (proposed adalimumab biosimilar)

Sep 17, 2021

Alvotech announced that the EU’s CHMP has adopted a positive opinion recommending the approval of AVT02 (proposed adalimumab biosimilar).

  • LinkedIn
Print Page Mail Article
View all BioBlast® Updates

Product specific reports based on extracts from our BioBlast® database

adalimumab | Humira® | AbbVie

aflibercept | Eylea® | Regeneron

bevacizumab | Avastin® | Roche/Genentech

cetuximab | Erbitux® | BMS/Merck

darbepoetin | Aranesp® | Amgen

denosumab | Prolia®/Xgeva® | Amgen

eculizumab | Soliris® | Alexion

etanercept | Enbrel® | Amgen

filgrastim (GCSF) | Neupogen® | Amgen

golimumab | Simponi® | Janssen

infliximab | Remicade® | Johnson & Johnson

natalizumab | Tysabri® | Biogen/Elan

omalizumab | Xolair® | Genentech / Novartis

pegfilgrastim | Neulasta® | Amgen

pembrolizumab | Keytruda® | Merck

pertuzumab | Perjeta® | Roche

ranibizumab | Lucentis® | Genentech

rituximab | Rituxan®/MabThera® | Genentech/Biogen

tocilizumab | Actemra® | Roche

trastuzumab | Herceptin® | Roche/Genentech

ustekinumab | Stelara® | Johnson & Johnson

View latest BioBlast® updates

Biosimilars Deals

2022 Deals

2021 Deals

2020 Deals

2019 Deals

2018 Deals

SUBSCRIBE TO PEARCE IP

Sign up to receive the latest life sciences industry news

Receive our weekly BioBlast®, regular life sciences Industry News and other Pearce IP updates straight to your inbox.

SUBSCRIBE
  • Our People
  • Our Capabilities
  • News
  • Blog
  • BioBlast®
  • Contact Us
  • Follow

Copyright © 2022 Pearce IP. All Rights Reserved. Privacy Statement